“Today’s approval for IMFINZI represents a paradigm shift, bringing the first perioperative immunotherapy to patients in the US with muscle-invasive bladder cancer and addressing a significant ...

The approval of Imfinzi was granted based on results from ... 2 "With this approval, we can now offer immunotherapy treatment to people living with limited-stage small cell lung cancer, which ...

IMFINZI was generally well tolerated ... AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a ...

Dave Fredrickson, Executive Vice President, Oncology Hematology Business Unit, AstraZeneca, said: “Today’s approval for IMFINZI represents a paradigm shift, bringing the first perioperative ...

Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “Today’s approval for Imfinzi represents a paradigm shift, bringing the first perioperative ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

followed by adjuvant Imfinzi after radical cystectomy in muscle invasive bladder cancer. The U.S. Food and Drug Administration has approved neoadjuvant treatment with the immunotherapy agent Imfinzi ...

Imfinzi-based regimen cuts the risk of disease progression, recurrence, or death by 32% in muscle-invasive bladder cancer. Calquence combo reduced disease progression or death risk by 27% in ...